Eiko LifeSciences Limited
BSE:540204 Stock Report
Eiko LifeSciences Balance Sheet Health
Financial Health criteria checks 5/6 Eiko LifeSciences has a total shareholder equity of ₹513.3M and total debt of ₹4.3M, which brings its debt-to-equity ratio to 0.8%. Its total assets and total liabilities are ₹549.3M and ₹35.9M respectively. Eiko LifeSciences's EBIT is ₹11.3M making its interest coverage ratio -16.1. It has cash and short-term investments of ₹31.3M.
Key information Interest coverage ratio -16.1x Cash ₹31.32m Equity ₹513.31m Total liabilities ₹35.95m Total assets ₹549.26m
Recent financial health updates
Show all updates
Second quarter 2025 earnings released: EPS: ₹0.22 (vs ₹0.12 in 2Q 2024) Oct 21
Eiko LifeSciences Limited to Report Q2, 2025 Results on Oct 19, 2024 Oct 11
Eiko LifeSciences Limited, Annual General Meeting, Sep 28, 2024 Sep 05
First quarter 2025 earnings released: EPS: ₹0.29 (vs ₹0.10 in 1Q 2024) Aug 14
Eiko LifeSciences Limited to Report Q1, 2025 Results on Aug 13, 2024 Aug 05
Full year 2024 earnings released: EPS: ₹0.73 (vs ₹0.92 in FY 2023) May 15
Eiko LifeSciences Limited to Report Q4, 2024 Results on May 13, 2024 May 08
Now 20% overvalued Apr 12
Now 21% overvalued Mar 18
Now 22% overvalued Mar 03
Insufficient new directors Mar 01
Third quarter 2024 earnings released: EPS: ₹0.24 (vs ₹0.31 in 3Q 2023) Feb 09
Eiko LifeSciences Limited to Report Q3, 2024 Results on Feb 08, 2024 Feb 03
New minor risk - Share price stability Jan 25
Second quarter 2024 earnings released: EPS: ₹0.12 (vs ₹0.31 in 2Q 2023) Nov 14
Eiko Lifesciences Limited Approves Appointment of Company Secretary and Compliance Officer Nov 09
Eiko LifeSciences Limited, Annual General Meeting, Sep 23, 2023 Aug 31
Eiko Lifesciences Limited Announces Resignation of Nilima Burghate as Company Secretary and Compliance Officer Aug 30
Eiko LifeSciences Limited Approves Appointment of Nilima A. Burghate as Company Secretary and Compliance Officer Aug 13 Eiko LifeSciences Limited has completed a Follow-on Equity Offering in the amount of INR 249.48801 million. Aug 12
New major risk - Shareholder dilution Aug 07
Whole-time Director recently sold ₹995k worth of stock Jul 21
First quarter 2024 earnings released: EPS: ₹0.10 (vs ₹0.10 in 1Q 2023) Jul 13
New minor risk - Share price stability Jul 06
Eiko LifeSciences Limited to Report Q1, 2024 Results on Jul 11, 2023 Jul 04
Investor sentiment improves as stock rises 19% Jul 03
Eiko Lifesciences Limited Announces Resignation of Avi Vijaykumar Mundecha as Company Secretary and Compliance Officer May 19
Full year 2023 earnings released: EPS: ₹0.92 (vs ₹0.90 in FY 2022) May 15
Third quarter 2023 earnings released: EPS: ₹0.31 (vs ₹0.07 loss in 3Q 2022) Jan 18
Eiko LifeSciences Limited to Report Q3, 2023 Results on Jan 17, 2023 Jan 10
Eiko LifeSciences Limited to Report Q2, 2023 Results on Oct 21, 2022 Oct 14
First quarter 2023 earnings released: EPS: ₹0.10 (vs ₹0.64 in 1Q 2022) Aug 14
Investor sentiment deteriorated over the past week Jul 07
Full year 2022 earnings released: EPS: ₹0.90 (vs ₹1.61 in FY 2021) Jun 08
Investor sentiment improved over the past week Jun 07
Eiko LifeSciences Limited, Annual General Meeting, Jun 25, 2022 Jun 03
Eiko LifeSciences Limited, Annual General Meeting, Jun 25, 2022 Jun 02
Full year 2022 earnings released: EPS: ₹0.90 (vs ₹1.61 in FY 2021) Apr 27
Third quarter 2021 earnings: Revenues and EPS in line with analyst expectations Feb 11
Eiko Lifesciences Limited Announces Chief Financial Officer Changes Feb 09
Eiko LifeSciences Limited to Report Q3, 2022 Results on Feb 08, 2022 Jan 30
Eiko LifeSciences Limited to Report Q3, 2022 Results on Feb 08, 2022 Jan 29
Company Secretary & Compliance Officer Chintan Doshi has left the company Aug 12
Narendra Investments (Delhi) Limited (BSE:540204) acquired Manufacturing Unit at MIDC, Badlapur. Jun 26
Narendra Investments (Delhi) Limited Appoints Rajkumar K Baheti as Additional Independent Director Feb 11
New 90-day high: ₹37.80 Feb 11
Narendra Investments (Delhi) Limited to Report Q3, 2021 Results on Feb 10, 2021 Jan 29
New 90-day high: ₹35.70 Jan 21
New 90-day high: ₹34.00 Dec 29
Narendra Investments (Delhi) Limited Appoints Umesh More as Additional Executive Director Nov 13
Narendra Investments (Delhi) Limited to Report Q2, 2021 Results on Nov 12, 2020 Nov 07
Full year earnings released - ₹4.99 loss per share Sep 12
New 90-day high - ₹38.65 Sep 09
New 90-day high - ₹35.10 Sep 03
Narendra Investments (Delhi) Limited to Report Q1, 2021 Results on Sep 08, 2020 Sep 02
Narendra Investments (Delhi) Limited to Report Q4, 2020 Results on Jun 27, 2020 Jul 17
Financial Position Analysis
Short Term Liabilities: 540204's short term assets (₹299.4M) exceed its short term liabilities (₹29.8M).
Long Term Liabilities: 540204's short term assets (₹299.4M) exceed its long term liabilities (₹6.1M).
Debt to Equity History and Analysis
Debt Level: 540204 has more cash than its total debt.
Reducing Debt: 540204's debt to equity ratio has reduced from 47.1% to 0.8% over the past 5 years.
Debt Coverage: 540204's operating cash flow is negative, therefore debt is not well covered.
Interest Coverage: 540204 earns more interest than it pays, so coverage of interest payments is not a concern.
Discover healthy companies Simply Wall St™ Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
{"enabled":true,"variant":{"name":"display-ssr-flag","enabled":true,"feature_enabled":true,"featureEnabled":true},"flagsReady":true,"flagsError":null}